ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / CRMD / forecast
KMDA (46) BLSM (42) PRTA (23) PHAT (33) ⌘ Pro Terminal →

CorMedix Inc. (CRMD) 12-Month Stock Forecast & Price Target Cone

$5.70 -25.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.43

CorMedix Inc. (CRMD) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY) →
ROARABLE C- • HOLD / WATCH Cap $443.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, CorMedix Inc. (NASDAQ: CRMD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $5.70 (-25.46% 1D, market cap $443.9M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, CRMD ranks #173 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CRMD compare to KMDA and BLSM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRMD carries a Roarable C- (59/100 RQD), trailing P/E of 3.7x, gross margin of 88.5%, and ROIC of 45.5%. By comparison, KMDA (Kamada Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $444.4M) and BLSM (BlossomHill Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $437.0M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while CRMD leads on capital efficiency (45.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRMD?
▼

Per CRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001410098), CorMedix Inc. generated $311.7M in revenue (+617.0% YoY), $163.1M in net income, and $172.8M in free cash flow against $826.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (89% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.43 (-4.77%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 55.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C-
025507510059
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-
Cash (16)Whales (4)SEC (14)Macro (10)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+0.5% Base Target
$14 Bull$6 Base$4 Bear
📬 FREE CRMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRMD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (59/100 Composite)
🔍 WHY CRMD SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 55.4% FCF Margin ($172.8M FCF) & 88.5% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (25% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
67
Grade B-$7.39+2.4% Next Q
Q2 (-2Q)
64
Grade C+$7.57+5.7% Next Q
Q3 (-1Q)
62
Grade C+$8.00-28.7% Next Q
Current
59
Grade C-$5.70+0.2% Hist 90D α
Trajectory: B- (67) → C- (59)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CRMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, CRMD faces multiple-compression risk if 3.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 86.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($7.74) or 200D SMA ($7.67) invalidates the momentum regime and cuts Target Base ($5.73) toward Bear Floor ($4.47).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CRMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 59%NO 41%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CRMD Position Size: $10,000

Shares at $5.70: 1754.4 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $4.47
$7,842
$-2,158 (-21.6%)
12M Consensus BaseTarget $5.73
$10,053
+$53 (+0.5%)
12M Bull Case BreakoutTarget $13.67
$23,982
+$13,982 (+139.8%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$674%A
Goldman SachsSector Coverage LeadBUY$1369%B
JP MorganUS Large-Cap ResearchHOLD$558%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CRMD Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CRMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.85%🛡️ HOLDING TREND SUPPORT
2026-11-03O $7.64H $7.64L $5.70C $5.70VOL 7.02M
RES: $8.32SUP: $5.59SMA50: $7.74SMA200: $7.67
$10.12$8.91$7.69$6.47$5.25RES $8.32SUP $5.59$5.702026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRMD Butterfly Map → + Track CRMD →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
-15.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CRMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CRMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRMD)

Health Care Rank #173 of 1016 ⚔️ KMDA vs CRMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRMD vs. KMDA, BLSM, PRTA, PHAT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CorMedix Inc. (CRMD) ranks #173 by composite RQD confidence (59/100, grade C-) and #463 by equity capitalization ($443.9M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while CRMD leads on capital efficiency and profitability with 45.5% ROIC and 88.5% gross margin. CRMD currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CRMD ACTIVE
CorMedix Inc.
C- 59/100 3.7x 88.5% 45.5% -25.46% $443.9M Benchmark Subject
KMDA
Kamada Ltd.
D 46/100 — — — -3.14% $444.4M /kmda-vs-crmd →
BLSM
BlossomHill Therapeutics Inc.
D- 42/100 — — — -9.60% $437.0M /blsm-vs-crmd →
PRTA
Prothena Corporation plc
E 23/100 — — -35.0% -4.62% $434.8M /prta-vs-crmd →
PHAT
Phathom Pharmaceuticals Inc.
E 33/100 — 87.1% -35.0% -7.72% $466.6M /phat-vs-crmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001410098

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CorMedix Inc. (CRMD) reported GAAP revenue of $311.7M (+617.0% vs. FY2024 revenue of $43.5M , and +127.4% cumulative change since FY2023) , GAAP net income of $163.1M, operating cash flow of $175.0M, and free cash flow of $172.8M (+440.6% YoY). On the balance sheet, CRMD closed FY2025 with $826.1M in total assets against $0 in total debt (Altman Z-Score: 1.81, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $311.7M $163.1M $175.0M $172.8M $826.1M —
FY2024 (FY) 2024-12-31 $43.5M -$17.9M -$50.6M -$50.7M $118.8M —
FY2023 (FY) 2023-12-31 $137.1M -$46.3M -$38.4M -$38.4M — —

3. CRMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, CorMedix Inc. (NASDAQ: CRMD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $5.70 (-25.46% 1D, market cap $443.9M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, CRMD ranks #173 in composite RQD confidence.

How does CRMD compare to KMDA and BLSM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRMD carries a Roarable C- (59/100 RQD), trailing P/E of 3.7x, gross margin of 88.5%, and ROIC of 45.5%. By comparison, KMDA (Kamada Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $444.4M) and BLSM (BlossomHill Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $437.0M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while CRMD leads on capital efficiency (45.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CRMD?

Per CRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001410098), CorMedix Inc. generated $311.7M in revenue (+617.0% YoY), $163.1M in net income, and $172.8M in free cash flow against $826.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (89% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CRMD trading relative to its 50-day, 200-day, and 52-week technical levels?

CRMD last traded at $5.70 (-25.46% on volume of 7,017,416 shares), positioning the stock -26.36% below its 50-day simple moving average ($7.74) and -25.68% below its 200-day simple moving average ($7.67). Across its 52-week range of $5.63 to $13.02, CRMD sits at the 0.9% percentile with a 14-day RSI of 37.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.99 to $6.41).

Direct Sub-Reports: CRMD RQD Cockpit CRMD 12M Forecast CRMD Earnings & Move CRMD Dividends & DRIP CRMD Insiders & 13F CRMD Whale Options CRMD Profit Sankey CRMD News & Why
ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CRMD — CorMedix Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:34:40Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CRMD scores 62 out of 100, a letter grade of C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

  • Fundamental Cash Engine: 16 / 20. The pillar cites ROIC of 45.5% and an FCF yield of 0%. The strong return on invested capital is the main support; the zero FCF yield in the market data means the current share price does not reflect a cash return to holders on that basis.
  • Whale / 13F Flow: 7 / 20. Institutional accumulation and options positioning are weak in this pillar.
  • Insider Conviction: 15 / 20. The pillar references SEC Form 4 and Congressional PTR cluster flow. Specific transactions are not itemized in the source data.
  • Macro Regime Fit: 10 / 20. Beta is 1.0 and the pillar notes sector sensitivity. The stock is therefore not characterized as a low-beta defensive holding.
  • Forensic Balance Sheet: 14 / 20. Altman Z-Score 1.81, Piotroski F-Score 8/9, Debt/Equity 0.5. The Piotroski reading is strong; the Altman reading sits in a range that warrants monitoring.

For a prospective investor, the rating describes a mixed profile: high reported profitability and a strong internal scoring of the balance sheet, offset by weak institutional flow, a zero FCF yield in the market data, and a macro/sector sensitivity score that is only mid-range. The share price has recently moved to a 52-week low, so the valuation multiples (P/E TTM 3.7, EV/EBITDA 3) should be read alongside the news flow below, which flags reimbursement risk.

Business

CorMedix Inc. is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations. The profile identifies the company by sector, industry, exchange, and market capitalization of $0.6B. Gross margin is reported at 88.5%, operating margin at 48.2%, and net margin at 52.3%.

Recent Catalysts & News Wire Analysis

  • RISK WATCH (RED): A Yahoo Finance item reports a fresh 52-week low tied to DaVita's warning of a sharp 2027 DefenCath reimbursement drop.
  • CATALYST (GREEN): A kalkine.ca item describes a commercial growth narrative for the company.
  • CATALYST (GREEN): A Simply Wall St item discusses EPS growth as a basis for the stock's case.
  • MARKET WIRE (YELLOW): A Seeking Alpha item reports a Rezzayo label expansion under FDA review.
  • MARKET WIRE (YELLOW): A MarketBeat item reports the stock reaching a new 1-year low.
  • MARKET WIRE (YELLOW): A Yahoo Finance comparison item covers CRMD against PRTA on value grounds.

The news wire is mixed: one red risk item on 2027 reimbursement, two green catalysts, and three yellow market-wire items. The Butterfly Supply-Chain Graph contains no supply-chain links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The one ripple the news wire does point to is reimbursement: the DaVita warning on 2027 DefenCath reimbursement implies that payer-side pricing decisions could transmit into the company's revenue, and an investor should monitor reimbursement announcements as the primary second-order channel.

Open Questions

  • What share of FY 2025 revenue is attributable to DefenCath versus other products, and how large is the 2027 reimbursement reduction referenced in the news wire?
  • What is the FY 2025 debt balance and the EPS figure for each reported period, given both are listed as N/A in the financials?
  • Why does the Roarable RQD rating assign a zero FCF yield in market data when FY 2025 reported FCF is $172.8M?
  • What are the 13F holder changes and Form 4 insider transactions behind the Whale and Insider pillar scores?
  • What is the status and expected timing of the Rezzayo label expansion under FDA review?

CRMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for CorMedix Inc. (CRMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CRMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CRMD Bull vs. Bear Conversation Board — What's Your Call at $5.70?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CRMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $6.95 (+21.9%)
📌 Pinned Debate

Reported FY 2025 operating income of $150.1M and ROIC of 45.5% show strong earnings power against a $595.5M market cap.

Picked up a starter position in CRMD in my $100K Virtual Cash book at $5.70. Reported FY 2025 operating income of $150.1M and ROIC of 45.5% show strong earnings power against a $595.5M market cap.. Trading inside a $5.63–$13.02 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

RetailWhale_TX 🐂 BULL

@FadeTheHype Shorting a 4/20 institutional whale-flow stock at $5.70 is dangerous when funds are rotating into Health Care.

FA FadeTheHype Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $4.79 (-16.0%)
Spot @ $5.70

The stock hit a fresh 52-week low on a DaVita warning of a sharp 2027 DefenCath reimbursement drop.

Here is the bear case nobody on the bull side wants to address on CRMD: The stock hit a fresh 52-week low on a DaVita warning of a sharp 2027 DefenCath reimbursement drop.. At 3.7x trailing P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%